Rotavirus vaccine
Cost-effectiveness — what published models estimate per unit of health impact
$/DALY
$36–175
WHO-CHOICE modeled
GiveWell
—
no GiveWell model
CE sources
2
Tier A · 350 studies
Source agreement
material
sources differ
Cost-effectiveness
Estimates are sourced in their native units and shown for comparison, not as literal costs. Sources use different frameworks — see each card for what it represents and how it was derived.
Modeled benchmarks ($/DALY)Tier A · standardized benchmark
WHO-CHOICE estimates are modeled at 50% population coverage, compared against the null set (no intervention) under generalized cost-effectiveness analysis. View WHO-CHOICE methodology →
$/DALY sources differ by 4.9x - a material difference.
Modeled regional estimates — not realized delivery costs.
Published study estimates ($/DALY)Tier B · context only
Tufts GHCEA · 350 studies, varied methods — explore the spread, not a single number.
Health-system
$102
median · n=225
Mixed
$151
median · n=102
Societal
$358
median · n=23
Filter the cohort
$119median of 350 studies · IQR $55–$350 · 3 cost-saving
Data completeness: not assessed (no country selected) · Evidence confidence: not assessed (no country selected)
Looking for supply/market data for Rotavirus vaccine? Select a country above, then open its intelligence page.